West Pharmaceutical Services, Inc. $WST Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd raised its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 81.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,874 shares of the medical instruments supplier’s stock after buying an additional 6,676 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in West Pharmaceutical Services were worth $3,254,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in WST. Zions Bancorporation National Association UT acquired a new stake in shares of West Pharmaceutical Services during the 1st quarter worth approximately $25,000. Quarry LP acquired a new stake in shares of West Pharmaceutical Services during the 1st quarter worth approximately $27,000. First Horizon Advisors Inc. raised its position in shares of West Pharmaceutical Services by 85.0% during the 1st quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 85 shares during the period. CVA Family Office LLC raised its position in shares of West Pharmaceutical Services by 573.3% during the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock worth $44,000 after purchasing an additional 172 shares during the period. Finally, Cromwell Holdings LLC raised its position in shares of West Pharmaceutical Services by 587.5% during the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 188 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on WST shares. Deutsche Bank Aktiengesellschaft set a $345.00 price target on West Pharmaceutical Services and gave the stock a “buy” rating in a research report on Friday, October 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Tuesday, October 14th. UBS Group increased their price target on West Pharmaceutical Services from $320.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, October 24th. Evercore ISI increased their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “outperform” rating in a research report on Thursday, October 23rd. Finally, Rothschild & Co Redburn started coverage on West Pharmaceutical Services in a report on Monday, September 15th. They issued a “buy” rating and a $311.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $349.20.

West Pharmaceutical Services Stock Up 0.5%

West Pharmaceutical Services stock opened at $284.81 on Thursday. The stock has a market cap of $20.49 billion, a price-to-earnings ratio of 42.19, a PEG ratio of 4.07 and a beta of 1.07. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. The company’s 50-day moving average price is $261.67 and its two-hundred day moving average price is $236.31. West Pharmaceutical Services, Inc. has a 52 week low of $187.43 and a 52 week high of $348.90.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, beating the consensus estimate of $1.67 by $0.29. The firm had revenue of $804.60 million for the quarter, compared to analysts’ expectations of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. West Pharmaceutical Services’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the company earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. On average, analysts expect that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.